Skip to main content
Erschienen in: International Journal of Colorectal Disease 12/2011

01.12.2011 | Original Article

Downregulation of caspase-10 predicting poor survival after resection of stage II colorectal cancer

verfasst von: Xiao-Gang Shen, Cun Wang, Yuan Li, Bin Zhou, Bin Xu, Lie Yang, Zong-Guang Zhou, Xiao-Feng Sun

Erschienen in: International Journal of Colorectal Disease | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to evaluate the prevalence and clinical significance of caspase-10 mRNA expression in stage II colorectal cancer.

Methods

Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) was used to analyze caspase-10 expression in cancer tissue and corresponding normal mucosa from 120 patients with stage II colorectal cancer. Variables were analyzed by Chi-square test or Fisher’s exact test. Survival was evaluated with method of Kaplan–Meier. Multivariate analysis was performed with Cox’s proportional hazards model.

Results

The expression of caspase-10 mRNA was found to be downregulated in cancer tissue compared to normal mucosa (P = 0.001). Poorly differentiated cancer showed lower mRNA expression than cancer with greater differentiation (P = 0.031). Univariate survival curves, estimated using the method of Kaplan–Meier, defined a significant association between caspase-10 expression and both overall survival (P = 0.012) and disease-free survival (P = 0.021). A multivariate analysis, performed by Cox’s proportional hazards regression model, confirmed that a low caspase-10 expression was the only significant factor to predict poor prognosis in patients with stage II colorectal cancer.

Conclusion

Our data indicate that caspase-10 expression, measured by quantitative real-time RT-PCR, is a possible prognostic factor in patients with stage II colorectal cancer.
Literatur
1.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P (2002) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRef Parkin DM, Bray F, Ferlay J, Pisani P (2002) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRef
2.
Zurück zum Zitat Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRef Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRef
3.
Zurück zum Zitat Sobin LH, Wittekin CH (1999) UICC TNM classification of malignant tumors, 5th edn. Wiley-Liss, New York Sobin LH, Wittekin CH (1999) UICC TNM classification of malignant tumors, 5th edn. Wiley-Liss, New York
4.
Zurück zum Zitat NIH Consensus Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264(11):1444–1450CrossRef NIH Consensus Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264(11):1444–1450CrossRef
5.
Zurück zum Zitat Riethmuller G, Schneider-Gadicke E, Schlimok G et al (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343:1177–1183PubMedCrossRef Riethmuller G, Schneider-Gadicke E, Schlimok G et al (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343:1177–1183PubMedCrossRef
6.
Zurück zum Zitat Moertel CG, Fleming TR, Macdonald JS et al (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321–326PubMed Moertel CG, Fleming TR, Macdonald JS et al (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321–326PubMed
7.
Zurück zum Zitat Dube S, Heyen F, Jenicek M (1997) Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis. Dis Colon Rectum 40:35–41PubMedCrossRef Dube S, Heyen F, Jenicek M (1997) Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis. Dis Colon Rectum 40:35–41PubMedCrossRef
8.
Zurück zum Zitat O’Connell MJ, Mailliard JA, Kahn MJ et al (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246–250PubMed O’Connell MJ, Mailliard JA, Kahn MJ et al (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246–250PubMed
9.
Zurück zum Zitat Mamounas E, Wieand S, Wolmark N et al (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17:1349–1355PubMed Mamounas E, Wieand S, Wolmark N et al (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17:1349–1355PubMed
10.
Zurück zum Zitat Glimelius B, Dahl O, Cedermark B et al (2005) Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 44:904–912PubMed Glimelius B, Dahl O, Cedermark B et al (2005) Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 44:904–912PubMed
11.
Zurück zum Zitat Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB (2002) Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 20:3999–4005PubMedCrossRef Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB (2002) Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 20:3999–4005PubMedCrossRef
12.
Zurück zum Zitat Gill S, Loprinzi CL, Sargent DJ et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797–1806PubMedCrossRef Gill S, Loprinzi CL, Sargent DJ et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797–1806PubMedCrossRef
13.
Zurück zum Zitat Sjostrom J, Bergh J (2001) How apoptosis is regulated, and what goes wrong in cancer. BMJ 322:1538–1539PubMedCrossRef Sjostrom J, Bergh J (2001) How apoptosis is regulated, and what goes wrong in cancer. BMJ 322:1538–1539PubMedCrossRef
14.
Zurück zum Zitat Wong BC, Zhu GH, Lam SK (1999) Aspirin induced apoptosis in gastric cancer cells. Biomed Pharmacother 53:315–318PubMedCrossRef Wong BC, Zhu GH, Lam SK (1999) Aspirin induced apoptosis in gastric cancer cells. Biomed Pharmacother 53:315–318PubMedCrossRef
15.
16.
Zurück zum Zitat Ghavami S, Hashemi M, Ande SR et al (2009) Apoptosis and cancer: mutations within caspase genes. J Med Genet 46:497–510PubMedCrossRef Ghavami S, Hashemi M, Ande SR et al (2009) Apoptosis and cancer: mutations within caspase genes. J Med Genet 46:497–510PubMedCrossRef
17.
Zurück zum Zitat Shen XG, Wang C, Li Y et al (2010) Downregulation of caspase-9 is a frequent event in patients with stage II colorectal cancer and correlates with poor clinical outcome. Colorectal Dis 12:1213–1218PubMedCrossRef Shen XG, Wang C, Li Y et al (2010) Downregulation of caspase-9 is a frequent event in patients with stage II colorectal cancer and correlates with poor clinical outcome. Colorectal Dis 12:1213–1218PubMedCrossRef
18.
Zurück zum Zitat Dydensborg AB, Herring E, Auclair J, Tremblay E, Beaulieu JF (2006) Normalizing genes for quantitative RT-PCR in differentiating human intestinal epithelial cells and adenocarcinomas of the colon. Am J Physiol Gastrointest Liver Physiol 290:G1067–G1074PubMedCrossRef Dydensborg AB, Herring E, Auclair J, Tremblay E, Beaulieu JF (2006) Normalizing genes for quantitative RT-PCR in differentiating human intestinal epithelial cells and adenocarcinomas of the colon. Am J Physiol Gastrointest Liver Physiol 290:G1067–G1074PubMedCrossRef
19.
Zurück zum Zitat Mygind T, Birkelund S, Birkebaek NH, Ostergaard L, Jensen JS, Christiansen G (2002) Determination of PCR efficiency in chelex-100 purified clinical samples and comparison of real-time quantitative PCR and conventional PCR for detection of Chlamydia pneumoniae. BMC Microbiol 2:17PubMedCrossRef Mygind T, Birkelund S, Birkebaek NH, Ostergaard L, Jensen JS, Christiansen G (2002) Determination of PCR efficiency in chelex-100 purified clinical samples and comparison of real-time quantitative PCR and conventional PCR for detection of Chlamydia pneumoniae. BMC Microbiol 2:17PubMedCrossRef
20.
Zurück zum Zitat Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45PubMedCrossRef Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45PubMedCrossRef
21.
Zurück zum Zitat Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36PubMedCrossRef Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36PubMedCrossRef
22.
Zurück zum Zitat Shibata D, Reale MA, Lavin P et al (1996) The DCC protein and prognosis in colorectal cancer. N Engl J Med 335:1727–1732PubMedCrossRef Shibata D, Reale MA, Lavin P et al (1996) The DCC protein and prognosis in colorectal cancer. N Engl J Med 335:1727–1732PubMedCrossRef
23.
Zurück zum Zitat Zaniboni A, Labianca R (2004) Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann Oncol 15:1310–1318PubMedCrossRef Zaniboni A, Labianca R (2004) Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann Oncol 15:1310–1318PubMedCrossRef
24.
Zurück zum Zitat Comoglio PM, Boccaccio C (2001) Scatter factors and invasive growth. Semin Cancer Biol 11:153–165PubMedCrossRef Comoglio PM, Boccaccio C (2001) Scatter factors and invasive growth. Semin Cancer Biol 11:153–165PubMedCrossRef
25.
Zurück zum Zitat Wong CW, Lee A, Shientag L et al (2001) Apoptosis: an early event in metastatic inefficiency. Cancer Res 61:333–338PubMed Wong CW, Lee A, Shientag L et al (2001) Apoptosis: an early event in metastatic inefficiency. Cancer Res 61:333–338PubMed
26.
Zurück zum Zitat Fernandes-Alnemri T, Armstrong RC, Krebs J et al (1996) In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc Natl Acad Sci USA 93:7464–7469PubMedCrossRef Fernandes-Alnemri T, Armstrong RC, Krebs J et al (1996) In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc Natl Acad Sci USA 93:7464–7469PubMedCrossRef
27.
Zurück zum Zitat Grenet J, Teitz T, Wei T, Valentine V, Kidd VJ (1999) Structure and chromosome localization of the human CASP8 gene. Gene 226:225–232PubMedCrossRef Grenet J, Teitz T, Wei T, Valentine V, Kidd VJ (1999) Structure and chromosome localization of the human CASP8 gene. Gene 226:225–232PubMedCrossRef
28.
Zurück zum Zitat Xu B, Zhou ZG, Li Y et al (2008) Clinicopathological significance of caspase-8 and caspase-10 expression in rectal cancer. Oncology 74:229–236PubMedCrossRef Xu B, Zhou ZG, Li Y et al (2008) Clinicopathological significance of caspase-8 and caspase-10 expression in rectal cancer. Oncology 74:229–236PubMedCrossRef
29.
Zurück zum Zitat Engels IH, Totzke G, Fischer U, Schulze-Osthoff K, Janicke RU (2005) Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner. Mol Cell Biol 25:2808–2818PubMedCrossRef Engels IH, Totzke G, Fischer U, Schulze-Osthoff K, Janicke RU (2005) Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner. Mol Cell Biol 25:2808–2818PubMedCrossRef
30.
Zurück zum Zitat Shin MS, Kim HS, Kang CS et al (2002) Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood 99:4094–4099PubMedCrossRef Shin MS, Kim HS, Kang CS et al (2002) Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood 99:4094–4099PubMedCrossRef
31.
Zurück zum Zitat Park WS, Lee JH, Shin MS et al (2002) Inactivating mutations of the caspase-10 gene in gastric cancer. Oncogene 21:2919–2925PubMedCrossRef Park WS, Lee JH, Shin MS et al (2002) Inactivating mutations of the caspase-10 gene in gastric cancer. Oncogene 21:2919–2925PubMedCrossRef
32.
Zurück zum Zitat Kischkel FC, Lawrence DA, Tinel A et al (2001) Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 276:46639–46646PubMedCrossRef Kischkel FC, Lawrence DA, Tinel A et al (2001) Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 276:46639–46646PubMedCrossRef
33.
Zurück zum Zitat Fong PY, Xue WC, Ngan HY et al (2006) Caspase activity is downregulated in choriocarcinoma: a cDNA array differential expression study. J Clin Pathol 59:179–183PubMedCrossRef Fong PY, Xue WC, Ngan HY et al (2006) Caspase activity is downregulated in choriocarcinoma: a cDNA array differential expression study. J Clin Pathol 59:179–183PubMedCrossRef
34.
Zurück zum Zitat Harada K, Toyooka S, Shivapurkar N et al (2002) Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 62:5897–5901PubMed Harada K, Toyooka S, Shivapurkar N et al (2002) Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 62:5897–5901PubMed
35.
Zurück zum Zitat Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ (2001) Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA 98:13884–13888PubMedCrossRef Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ (2001) Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA 98:13884–13888PubMedCrossRef
36.
Zurück zum Zitat Li J, Chen P, Sinogeeva N et al (2002) Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J Biol Chem 277:49504–49510PubMedCrossRef Li J, Chen P, Sinogeeva N et al (2002) Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J Biol Chem 277:49504–49510PubMedCrossRef
37.
Zurück zum Zitat Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N (2000) Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 60:4315–4519PubMed Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N (2000) Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 60:4315–4519PubMed
38.
Zurück zum Zitat Kolenko V, Uzzo RG, Bukowski R et al (1999) Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. Cancer Res 59:2838–2842PubMed Kolenko V, Uzzo RG, Bukowski R et al (1999) Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. Cancer Res 59:2838–2842PubMed
39.
Zurück zum Zitat Giotakis J, Gomatos IP, Alevizos L et al (2010) Bax, cytochrome c, and caspase-8 staining in parotid cancer patients: markers of susceptibility in radiotherapy? Otolaryngol Head Neck Surg 142:605–611PubMedCrossRef Giotakis J, Gomatos IP, Alevizos L et al (2010) Bax, cytochrome c, and caspase-8 staining in parotid cancer patients: markers of susceptibility in radiotherapy? Otolaryngol Head Neck Surg 142:605–611PubMedCrossRef
40.
Zurück zum Zitat Pingoud-Meier C, Lang D, Janss AJ et al (2003) Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res 9:6401–6409PubMed Pingoud-Meier C, Lang D, Janss AJ et al (2003) Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res 9:6401–6409PubMed
41.
Zurück zum Zitat Fulda S, Poremba C, Berwanger B et al (2006) Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma. Cancer Res 66:10016–10023PubMedCrossRef Fulda S, Poremba C, Berwanger B et al (2006) Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma. Cancer Res 66:10016–10023PubMedCrossRef
Metadaten
Titel
Downregulation of caspase-10 predicting poor survival after resection of stage II colorectal cancer
verfasst von
Xiao-Gang Shen
Cun Wang
Yuan Li
Bin Zhou
Bin Xu
Lie Yang
Zong-Guang Zhou
Xiao-Feng Sun
Publikationsdatum
01.12.2011
Verlag
Springer-Verlag
Erschienen in
International Journal of Colorectal Disease / Ausgabe 12/2011
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-011-1239-z

Weitere Artikel der Ausgabe 12/2011

International Journal of Colorectal Disease 12/2011 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.